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Abstract: By studying the literature about tetracyclines (TCs), it becomes clearly evident 
that TCs are very dynamic molecules. In some cases, their structure-activity-relationship 
(SAR) are well known, especially against bacteria, while against other targets, they are 
virtually unknown. In other diverse fields of research—such as neurology, oncology and 
virology—the utility and activity of the tetracyclines are being discovered and are also 
emerging as new technological fronts. The first aim of this paper is to classify the 
compounds already used in therapy and prepare the schematic structure that includes the 
next generation of TCs. The second aim of this work is to introduce a new framework for 
the classification of old and new TCs, using a medicinal chemistry approach to the 
structure of those drugs. A fully documented Structure-Activity-Relationship (SAR) is 
presented with the analysis data of antibacterial and nonantibacterial (antifungal, antiviral 
and anticancer) tetracyclines. The lipophilicity and the conformational interchangeability 
of the functional groups are employed to develop the rules for TC biological activity. 
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1. Introduction 
The number of articles published on tetracycline drugs has reached the threshold of 50,000 papers 
since 1948. Over the last 10 years, technological fields are emerging in bacteriology and cellular 
physiology of eukaryotic cells. However, chemical mechanisms of tetracyclines are not completely 
understood in terms of their function in human cells and, to this day, no (Q)SAR model is validated 
without doubts. Tetracyclines were first discovered by Dr. Benjamin Dugger of Lederle Laboratories 
in the mid 1940s as the fermentation product of an unusual golden-colored soil bacterium aptly named 
Streptomyces aureofacians [1]. Tetracyclines (TCs) are a class of antibiotics able to inhibit protein 
synthesis in gram positive and gram negative bacteria by preventing the attachment of  
aminoacyl-tRNA to the ribosomal acceptor (A) site [2]. This mechanism has been confirmed by X-ray 
crystallography [3]. TCs bind specifically to the bacterial ribosome and not specifically with 
eukaryotic ribosomes. TCs belong to a notable class of biologically active and commercially valuable 
compounds. This fact may be simply illustrated by mentioning the most important clinical application 
of TCs, their employment as broad antimicrobial-spectrum antibiotics for human and veterinary use [4]. 
While they were initially developed as antibiotics, they also hold promise as non-antibiotic compounds 
for future study and use. Tetracyclines, as dynamics entities, possess unique chemical and biological 
characteristics that may explain their ability to interact with so many different cellular targets, 
receptors and cellular properties [5]. The discovery of new uses for tetracyclines and their novel 
biological properties against both prokaryotes and eukaryotes is currently under investigation by 
numerous scientists throughout the world. TCs as drugs show only few side effects: one is chelation of 
calcium and subsequent intercalation in bones and teeth while the other is somewhat like 
photosensitizing drugs, given their phototoxic action on keratinocytes and fibroblasts. The mechanisms 
of phototoxicity in vitro and in vivo are not yet entirely clear [6]. 
Figure 1. Structure-Activity-Relationship (SAR) of Tetracyclines (TCs). Shaded: Contact 
region with 30S rRNA. In blue polygonal: same anthracycline region. 
Upper peripheral modification region 
 
Lower peripheral non modifiable region  
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2. Pharmacological Activities 
The therapeutic uses are as follows: antibacterial and non-antibacterial. In the literature, these uses 
fall into five main categories, namely: (I) newer and more potent tetracyclines used in anitibacterial 
resistance [7], (II) the nonantibacterial uses of tetracyclines targeted toward inflammation [8] and 
arthritis [9–12]; (III) in neurology: (a) In tissue destructive diseases acting like antifibrilogenics [13]; 
(b) Inhibiting caspase-1 and caspase-3 expression in Hungtington’s disease [14]; (c) Ischemia [15];  
(d) Parkinson’s [16] and other neurodegeneration diseases; (IV) antiviral and anticancer [17–19]; (V) 
Tet repressor controlled gene switch [20]. 
2.1. Antibacterial Use 
Currently, as a consequence of their overuse, bacteria have developed TC resistance (efflux pump 
type) as opposed to the oldest compounds. Medicinal chemists with the intention to optimize structure 
and improve the antibacterial power have successfully introduced an alkaline group on C-9 of 
minocycline skeleton, starting as a compound from total synthesis: Tigecycline (a patent of Pfizer and 
Wyeth, available in therapy from 2005). Searching for new molecules, it is not only important to study 
the binding of drugs specifically to bacterial ribosomes, but also to understand how the tetracycline 
skeleton can act as a chelator and ionophore [21]. Moreover, the next generation of antibacterial 
tetracyclines is currently in progress and will be highly specific for bacterial species and will contain 
new groups and new rings on the classical skeleton [22]. Mechanism of action of TCs is divided into 
two categories: “Typical”, if they act as bacteriostatic; “atypical”, if they act as batericidic. Typical 
TCs bind specifically to the bacterial ribosomal subunits. All of them that do not have ribosomes as 
their primary target are considered atypical. Moreover, these atypical mechanisms of action are very 
toxic both for prokaryotes and eukaryotes (even for mammalian cells). Until now, all TCs used in 
therapy are broad-spectrum against microbial agents, but researchers are developing a platform to 
introduce in therapy only novel TCs with a narrow-spectrum for infectious diseases [23]. 
2.2. Non-Antibacterial Use 
Both laboratory and clinical studies have investigated the anti-inflammatory properties of 
tetracyclines. These include: Acting as an inhibitor forlymphocytic proliferation [9], suppression of 
neutrophilic migration [10], inhibition of phospholipase A2 [11] and accelerated degradation of nitric 
oxide synthetase [12]. 
In recent times, starting from the end of the 1990s [24], TCs have showed to be anti-caking of  
β-amyloid protein and are therefore useful in the treatment of neurodegenerative diseases like 
Alzheimer’s and the Prion Diseases [25,26]. In particular, Minocycline reduces inflammation and 
protects against focal cerebral ischemia with a wide therapeutic window [27]. Also, Minocycline 
inhibits caspase-3 expression and delays mortality in a transgenic mouse model of Huntington  
Disease [28]. Researchers focused on the mechanisms of intracellular pathway communication and 
genetic control leading to the attenuation of microglia activation [29] and protection of Schwann  
cells [30]. 
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In the same way that tetracyclines act as pro-apoptotics in neuronal cells, they also act in peripheral 
metastasis of generalized tumor cells. Experimental data using various carcinoma cell lines and animal 
carcinogenesis models showed that doxycycline, minocycline and chemical modified tetracyclines 
(CMTs) inhibit tumor growth by inhibiting matrix metalloproteinase (MMPs) and by having a direct 
effect on cell proliferation [18,19]. The first use of tetracyclines in viral infections was reported by 
Lemaitre in 1990 [31]. In 2005, Zink [32] documented the first anti-inflammatory and neuroprotective 
activity of an antibiotic against a highly pathogenic viral infection. Minocycline is also significantly 
effective against West Nile virus replication in cultured human neuronal cells and subsequently 
prevented virus-induced apoptosis [33]. 
The tetracycline-controllable expression system offers a number of advantages: Strict on/off 
regulation, high inducibility, short response times, specificity, no interference with the cellular 
pathway, bioavailability of a non-toxic inducer, and dose dependence. The tet-off system [34], which 
uses the tetracycline-responsive transcriptional activator (tTA), and the tet-on system [35], which uses 
the reverse tetracycline-responsive transcriptional activator (rtTA), provides negative and positive 
control of transgene expression. 
3. Classification of Tetracyclines 
Historically, tetracyclines are considered First generation if they are obtained by biosynthesis such 
as: Tetracycline, Chlortetecycline, Oxytetracycline, Demeclocycline. Second generation if they are 
derivatives of semi-synthesis such as: Doxycycline, Lymecycline, Meclocycline, Methacycline, 
Minocycline, Rolitetracycline. Third generation if they are obtained from total synthesis such as: 
Tigecycline. However, some researchers consider Tigecycline to be distinct from other tetracyclines 
drugs and are considered as a new family of antibacterials called Glycylcyclines. 
The present paper introduces a new schematic point of view about the denomination and the 
classification of Tetracycline-Structure-Based drugs. In the years to come, new TCs, which now are 
advanced in the clinical trials (Phase III of Pharmaceutical Trials Protocol), will be available in 
therapy. TCs obtained via total synthesis, such as Tigecycline, are considered members of the Third 
generation if they show wide spectrum activities (both Gram+ and Gram−) Aminomethylcycline 
derivatives are considered in the same way as Glycylcycline (Scheme 1). In the last five years, 
thousands of medicinal chemists around the world have synthesized, tested and patented more than 
310 tetracycline similar compounds, in particular in the USA [36]. Harvard University [37] and 
Tetraphase [38] made available pentacycline antibacterials (a structural modification of Doxycycline 
with five rings), azatetracycline and flurocycline (heteroatoms insert into the D ring, as show in Figure 1) 
and alkylaminotetracycline antibacterials. 
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Scheme 1. Wide-spectrum of tetracycline activities as antibiotic drugs. TCs are subdivided in: Antibacterial (with typical and atypical 
mechanism of action), antifungal and antineoplastic. 
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All these compounds are the “logical results of modification around the four rings of tetracyclines 
that historically started with the master work of Golub and McNamara [39,40] when, thirty years ago, 
the first eight compounds called chemically modified tetracyclines (CMTs) were introduced in the 
literature. In 1983, Golub and McNamara [39,40] introduced a new concept concerning the therapeutic 
usefulness of tetracyclines. They proposed two main ideas. First, tetracyclines, but not other 
antibiotics, can inhibit the activity of collagenase—a specific collagenolytic metallo-neutral protease 
produced by host tissues which has repeatedly been implicated in periodontal destruction. Second, this 
newly discovered property of the drugs could provide a novel approach to the treatment of diseases, 
such as periodontal diseases, but also certain medical disorders (e.g., non-infected corneal ulcers), 
which involve excessive collagen destruction. In these cases, TCs appear to inhibit collagenase activity 
by a mechanism unrelated to the drug’s antibacterial efficacy. In fact, all CMTs have been modified by 
the removal of the dimethylamino group from the C4 position on the A ring. To better classify the new 
compounds it is very important to understand which chemical properties make it possible for 
tetracycline-structure-based drugs to act as a “chameleonic” entity. As discussed in the previous 
paragraph, TCs can be considered as wide-spectrum antibiotics versus bacteria, fungi, virus and cancer 
cells. In this view TCs can be considered an optimum example of multi target drugs and the first well 
documented in the literature. Moreover, Doxorubicin and all the other anthracyclines are structurally 
correlated to tetracyclines and it is appropriate to classify them both in the same scheme because of 
their chemical similarities, chemical physics properties and their use as anti-cancer drugs. 
4. Chemical Biology of Tetracyclines 
4.1. Structures Activities Relationship (SAR) 
Figure 1 shows the TCs rigid skeleton with the numeration of the four rings, groups and the upper 
and lower sides of the molecule such as they are commonly called. Many of the chemical 
modifications of both the first and second generation tetracyclines produced variably active or inactive 
compounds. An active tetracycline (antibacterial activity) must possess a linearly arranged DCBA 
naphthacene ring system with an A-ring C1-C3 diketo substructure and an exocyclic C2 carbonyl or 
amide group. All TCs that act as inhibitor of protein synthesis in bacteria need the amino group in 
position C4 and keto-enolic tautomers in position C1 and C3 of the A ring. The amino group in the C4 
position is pivotal for the antibacterial activities (Scheme 2). A C4-dimethylamino group with its 
natural 4S isomer is required for optimal antibacterial activity, while epimerization to its 4R isomer 
decreases Gram–negative activity [41]. It also requires a C10-phenol and C11-C12 keto-enol 
substructure in conjunction with a 12a-OH group (Scheme 2) outlining a lower peripheral region. All 
those substituents, with the respective tautomeric equilibrium, are indispensable for recognition and 
bonding in ribosomal subunits, where chemical modification abolishes bioactivity. Modification of the 
amide in C2 is possible but with loss of potency. Positions C5 to C9 can be chemically modified to 
affect their bioactivity and they are designed for the upper peripheral regions, generating derivatives 
with varying antibacterial activity. Groups R1, R2 and R3 are modifiable to give more selectivity to 
the biological target in antifungal TCs, but not for the antibacterial activity (Scheme 2). The D ring is 
the most flexible to change. All modifications of group R4, R5 and R6 are allowed to give highly 
bacterial specificity and deep changing in pharmacokinetics as result of modifying log P (Table 1). 
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Scheme 2. Structure Activity Relationship of Tetracycline family drugs. Since their 
introduction in therapy, into the early 1950s, tetracyclines have constantly been modified 
according to the capabilities of the pharmaceutical laboratories in a given time. Starting as 
antibacterials, tetracyclines have demonstrated antifungal, antiviral and antitumor 
properties as well. Nowadays, the new tetracyclines are the most powerful drugs for 
serious skin infection and the future prospective goal is to separate their anti-inflammatory 
properties form the antibiotic properties. 
 
Table 1. Experimental data of TCs and their pharmacokinetics values (adapted from 
www.drugbank.ca). 
Compounds LogP LogS 
% Enteric 
absorption 
% Serum protein 
binding 
Renal 
clearance 
(mL/min) 
Half-Life 
(hours) 
Oxytetracycline −1.3 −3.14 58 30 90 10 
Tetracycline −0.3 −3.12 80 60 65 9 
Doxycycline −0.2 −2.87 93 85 16 15 
Demeclocycline 0.2 −2.52 66 75 31 13 
Chlorotetracycline - - 30 55 35 6 
Meclocycline - - - - - - 
Minocycline 0.5 - 95 90 10 20 
Rolitetracycline - - - - - - 
Tigecycline 0.8 - - 90 - 32 
Doxorububicine −0.5 - - 70 - 55 
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4.2. Diverse Mechanism of Action 
Hydroxyl groups are a source of radical oxygen species (ROS) that irreversibly damage 
macromolecules such as DNA, RNA and proteins. All these effects are considered as fundamental to in 
cellular death for oxidative stress. In the case of antitumor anthracyclines and CMT-3, these act to 
block the enzymatic transcriptional complex formation on DNA and then induce apoptotic events. 
Antifungal and antitumor TCs act in a different way from antibacterial TCs. Once passed into the 
eukaryotic cells, TCs change the electronic balance equilibrium sequestering divalent ions (e.g., Ca
2+
) 
much more then monovalent ions (e.g., K
+
). It is known that TC forms complexes in different positions 
with calcium and magnesium ions that are available in the blood plasma [42,43]. Most tetracycline 
acted as bacteriostatic or typical, as protein synthesis inhibitors against bacteria. But it was found that 
more lipophilic tetracyclines were atypical, with a bactericidal mechanism that relied on membrane 
damage (as ionophores). Now, medicine is showing the tetracyclines as a family are chemically and 
biologically dynamic, with multiple mechanisms of activity and capable of interacting with multiple 
targets, either ribosomal or cellular membranes. 
4.3. Structural Dynamics 
TCs have different acid groups in their structure and the possibility to adopt different 
conformations. The different proton-donating groups of this molecule offer several possibilities for 
metal ion substitution. The complexation with metal ions increases the stability of the various TC 
derivatives. In 1999, Duarte [44] developed a computational and experimental study to evaluate the 
weight of the various chemical tautomeric behaviors of tetracyclines in solution. The degree of 
protonation of TC depends upon the specific tautomers that in aqueous solution are more stable than 
others. It is important to analyze all the possible tautomers of this molecule in their different degrees of 
protonation and conformations to understand the role of tautomerism in the chemical behavior of TC. 
Duarte [44] optimized the structures of all 64 tautomers and calculated their heats of formation (ΔHf°). 
There are different tautomers in equilibrium in each degree of protonation of TC. They have similar 
stabilities and they are present in considerable amount in the medium. All the substituent groups 
contribute with steric effects and polar induced vectors to the geometrical shape of each compound 
(Figure 2). 
5. Methodology 
In this work a new framework is introduced for the classification of old and novel TCs and their 
Structure Activity Relationship. The possibility to open access of large chemical data base has changed 
enormous. All data reporting in this paper has been verified and compared with the National Health 
Institution Public Library (Bethesda, MD) using PubChem Project. The computational analysis has 
been performed on a data set of 1325 TCs with a similarity score of 90%, starting from more than 
322,000 compounds recorded in PubChem (this paper is in preparation). From that set were chosen the 
best in class TCs with a similarity score major of 95% (Scheme 1). For each TC selected, PubChem 
shows at least 112 tautomers and conformers structure with “rule of five” data. The new classification 
proposed is based on a medicinal chemistry approach due to the complexity of the novel TCs drugs, 
Antibiotics 2012, 1                            
 
 
9 
e.g.,: Chemical modified tetracycline (CMT), Anthracycline drugs (Doxorubicin) and structurally-
correlated-tetracycline (Pentacyclin, Glycylcyclin, Flurocyclin, Aminomethylcyclin and Azatetracylin).  
Figure 2. 3D geometrical shape of Tetracycline (A), Tigelcycline (B) and SF2575 (C). 
TCs show different conformation and biological activities due their functional groups on 
the same rigid molecular skeleton. 
 
 
 
 
 
A 
B 
C 
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6. Conclusions 
The role of lipophilicity of TCs is the main factor to explain the biological potency and dynamics of 
this old family of drugs. It is important to understand the conformational flexibility and the affinity of 
TCs of metals ions due to the several functional groups present in the molecular skeleton to obtain a 
significant SAR study. After more than 60 years of scientific investigation, TCs are considered a 
master example of the pleitropic family of compounds with promising therapeutic properties. Due to 
the wide use in therapy and their low toxicity, TCs can be considered the first Multi-Target Drugs fully 
and well discussed in the history of pharmacology. 
Newer and more potent antibacterial compounds can be expected to fight the tetracycline-resistant 
pathogens. New, third-generation derivatives have been designated to be more potent, especially 
against bacteria possessing ribosomal protection and efflux mechanisms. TCs have increased in 
potency over time compared to other structural classes of antibiotics. TCs have shown a complex 
mechanism of action towards various targets due to their conformations under physiological 
conditions. Such conformations, depending on pH and metal ion concentrations, allow TCs to act in a 
“chameleonic-like” manner in a large number of diseases. As already suggested, the future of TCs will 
have increased utility as one of the best anti-inflammatory drugs.  
Acknowledgments 
This review is dedicated to my wife and to my family-in-law for their unconditional support to my 
work. The author wishes to thank Karina Mastronardi for her comments in the editing of this paper. 
Conflict of Interest 
The author declares no conflict of interest.  
References and Notes 
1. Wainwright, M. Miracle Cure: The Story of Antibiotics; Blackwell: Oxford, UK, 1990. 
2. Connell, S.; Tracz, R.; Nierhaus, D.; Taylor, K.H.; Diane, E. Ribosomal Protection Proteins and 
Their Mechanism of Tetracycline Resistance. Antimicrob. Agents Chemother. 2003, 47, 3675–3681. 
3. Broderson, D.E.; Clemenson, W.M.; Carter, A.P.; Morgan-Warren, R.J.; Wimberly, B.T.; 
Ramakrishan, V. The structural basis for the action of the antibiotics tetracycline. Cell 2000, 103, 
1143–1154. 
4. Nelson, M.L.; Ismail, M.Y. The Antibiotic and Nonantibiotic Tetracyclines. Comp. Med. Chem. 
2007, 7, 742–775. 
5. Nelson, M.L. Chemical and Biological Dynamics of Tetracycline. Adv. Dent. Res. 1998, 12, 5–11. 
6. Carlotti, B.; Fuoco, D.; Elisei, F. Fast and ultrafast spectroscopic investigation of tetracycline 
derivatives in organic and aqueous media. Phys. Chem. Chem. Phys. 2010, 12, 15580–15591. 
7. Chopra, I.; Roberts, M. Tetracycline antibiotics: Mode of action, application, molecular biology 
and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 2001, 65, 232–260. 
Antibiotics 2012, 1                            
 
 
11 
8. D’Agostino, P.; Ferlazzo, V.; Milano, S.; La Rosa, M.; Di Bella, G. Anti-inflammatory effects of 
chemically modified tetracyclines by the inhibition of nitric oxide and interleukin-12 synthesis in 
J774 cell line. Int. Immunopharmacol. 2001, 1, 1765–1776. 
9. Thong, Y.H.; Ferrante, A. Inhibition of mitogen-induced human lymphocyte proliferative 
responses to tetracycline analogues. Clin. Exp. Immunol. 1979, 35, 443–446. 
10. Martin, R.R.; Warr, G.A.; Couch, R.B.; Yeager, H.; Knight, V. Effects of tetracyclines on 
leukotaxis. J. Infect. Dis. 1974, 129, 110–116. 
11. Pruzanski, W.; Laliberte, F.; Stefanski, E.; Vadas, P. Inhibition of enzymatic activity of 
phospholipase A2 by minocycline and doxycycline. Biochem. Pharmacol. 1992, 44, 1165–1170. 
12. Amin, A.R.; Patel, R.N.; Thakker, G.D.; Lowenstein, C.J. Post-transcriptional regulation of 
inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically 
modified tetracyclines. FEBS Lett. 1997, 410, 259–264. 
13. Cosentino, U.; Varí, M.R.; Saracino, A.A.G.; Pitea, D.; Moro, G.; Salmona, M. Tetracycline and 
its analogues as inhibitors of amyloid fibrils: Searching for a geometrical pharmacophore by 
theoretical investigation of their conformational behavior in aqueous solution. J. Mol. Model. 
2005, 11, 17–25. 
14. Chen, M.; Ona, V.O.; Li, M.; Ferrante, R.J.; Fink, K.B.; Zhu, S.; Bian, J.; Guo, L.; Farrell, L.A.; 
Hersch, S.M.; et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality 
in a transgenic mouse model of Huntington disease. Nat. Med. 2000, 6, 797–801. 
15. Yrjanheikki, J.; Tikka, T.; Keinanen, R.; Chan, P.; Koistinaho, J. A tetracycline derivative, 
minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide 
therapeutic window. Proc. Natl. Acad. Sci. USA 1999, 96, 13495–13500. 
16. Thomas, M.; Le, W.D.; Jankovic, J. Minocycline and Other Tetracycline Derivatives: A 
Neuroprotective Strategy in Parkinson’s Disease and Huntington’s Disease. Clin. Neuropharmacol. 
2003, 26, 18–23. 
17. Stetler-Steveson, W.G. Extracellular matrix 6: Role of matrix metalloproteinases in tumor 
invasion and metastasis. FASEB J. 1993, 7, 1434–1441. 
18. Duivenvoorden, W.C.; Hirte, H.W.; Singh, G. Use of tetracycline as an inhibitor of matrix 
metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invas. Metast. 
1997, 17, 312–322. 
19. Rubins, J.B.; Charboneau, D.; Alter, M.D.; Bitterman Kratzke, R.A. Inhibition of mesothelioma 
cell growth in vitro by doxycycline. J. Lab. Clin. Med. 2001, 138, 101–106. 
20. Ermak, G.; Cancasci, V.J.; Davies, K.J.A. Cytotoxic effect of doxycycline and its implications for 
tet-on gene expression systems. Anal. Biochem. 2003, 318, 152–154. 
21. Lambs, L.; Reverend, B.D.; Kozlowski, H.; Berthon, G. Metal-ion tetracycline interactions in 
biological fluids. 9. Circular dichroism spectra of calcium and magnesium complexes with 
tetracycline, oxytetracycline, doxycycline and chlortetracycline and a discussion of their binding 
modes. Inorg. Chem. 1988, 41, 638–641. 
22. Charest, M.G.; Lerner, C.D.; Brubaker, J.D.; Siegel, D.R.; Myers, A.G. A convergent 
enantioselective route to structurally diverse 6-deoxytetracycline antibiotics. Science 2005, 308, 
395–398. 
Antibiotics 2012, 1                            
 
 
12 
23. Nelson, M.L.; Levy, S. The history of the tetracyclines. Ann. NY Acad. Sci. Antimicrob. Ther. Rev. 
2011, 1241, 17–32. 
24. Howlett, D.; George, A.; Owen, D.; Ward, R.; Mqarkekwell, R. Common structural determine the 
effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitor of Alzheimer B-amyloid 
fibril formation. Biochem. J. 1999, 343, 419–423. 
25. Cosentino, U.; Pitea, D.; Moro, G.; Saracino, A.; Caria, P.; Vari, R.; Colombo, L.; Forloni, G.; 
Tagliavini, F.; Salmona, M. The anti-fibrillogenic activity of tetracyclines on PrP 106–126:  
A 3D-QSAR study. J. Mol. Model. 2008, 14, 987–994. 
26. De Luigi, A.; Colombo, L.; Diomede, L.; Capobianco, R.; Mangieri, M. The Efficacy of 
Tetracycline in Peripheral and intracerebral Prion Infection. PLoS One 2008, 3, e1888.  
27. Weng, Y.C.; Kriz, J. Differential neuroprotective effects of a minocycline-based drug cocktail in 
transient and permanent focal cerebral ischemia. Exp. Neurol. 2007, 204, 433–442. 
28. Khan, M.; Musarrat, J. Interactions of tetracycline and its derivatives with DNA in vitro in 
presence of metal ions. Int. J. Biol. Macromol. 2003, 33, 49–56. 
29. Tang, X.N.; Wang, O.; Koike, M.A.; Chang, D.; Goris, M.L.; Blankenbag, F.G. Monitoring the 
protective effects of minocycline treatment with radiolabeled annexin V in an experimental model 
of focal cerebral ischemia. J. Nucl. Med. 2007, 11, 1822–1828. 
30. Lemaitre, M.; Guetard, D.; Henin, Y.; Montagnier, L.; Zerial, A. Protective activity of tetracycline 
analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells. Res. 
Virol. 1990, 141, 5–16. 
31. Zink, M.C.; Uhrlaub, J.; DeWitt, J.; Voelker, T.; Bullock, B.; Mankowski, J. Neuroprotective and 
anti-human immunodeficiency virus activity of minocycline. JAMA 2005, 293, 2003–2011. 
32. Michaelis, M.; Kleinschmidt, M.C.; Doerr, H.W.; Cinatl, J. Minocycline inhibits West Nile virus 
replication and apoptosis in human neuronal cells. J. Antimicrob. Chemother. 2007, 60, 981–986. 
33. Dutta, K.; Basu, A. Use of minocycline in viral infections. Indian J. Med. Res. 2011, 133, 467–470. 
34. Grossen, M.; Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-
responsive promoters. Proc. Natl. Acad. Sci. USA 1992, 89, 5547–5551. 
35. Halterman, M.W. An improved method for the study of apoptosis-related genes using the tet-on 
system. J. Biomol. Screen. 2011, 16, 332–337. 
36. http://www.freshpatents.com/ and Google Patents Search Engine (accessed on 19 May 2012). 
37. Prof. Andrew G. Myers, Department of Chemistry, Harvard University, Boston, USA. 
http://www.chem.harvard.edu/groups/myers/index.html/ (accessed on 19 May 2012). 
38. Xiao, X.-Y.; Hunt, D.K.; Zhou, J.; Clark, R.B.; Dunwoody, N.; Fyfe, C.; Grossman, T.H.; 
O’Brien, W.J.; Plamondon, L.; Rönn, M.; et al. Fluorocyclines. 7-Fluoro-9-pyrrolidinoacetamido-
6-demethyl-6-deoxytetracycl: A Potent, Broad Spectrum Antibacterial Agent. J. Med. Chem. 
2012, 55, 597–605. 
39. Golub, L.M.; Lee, H.M.; McNamara, T.F. Minocycline Reduce Gingival Collagenolytic Activity 
during Diabetes: Preliminary Observations and a Proposed New Mechanism of Action.  
J. Periodontal Res. 1983, 18, 516–526. 
40. McNamara, T.F.; Golub, L.M.; D’Angelo, G. The Synthesis and Characterization of a  
Non-antibacterial Chemically Modified Tetracycline. J. Dent. Res. 1986, 65, 266. 
Antibiotics 2012, 1                            
 
 
13 
41. Doershuk, A.P.; Bitler, B.A.; McCormick, J.R.D. Reversible isomerization in the tetracycline 
family. J. Am. Chem. Soc. 1955, 77, 467. 
42. Silvia, P.P.; Guerra, W.; Silveira, J.N.; Ferreira, A.M.C.; Bortolotto, T.; Fischer, F.L.; Terenzi, H.; 
Neves, A.; Pereira-Maia, E.C. Two new ternary complexes of copper (II) with tetracycline or 
doxycycline and 1,10-Phenantroline and their potential as antitumoral: Cytotoxicity and DNA 
cleavage. Inorg. Chem. 2011, 50, 6414–6424. 
43. Bortolotto, T.; Silva, P.P.; Neves, A.; Pereira-Maia, E.C.; Terenzi, H. Photoinduced DNA 
Cleavage promoted by two Copper (II) complexes of tetracyclines and 1,10-Phenanthroline. 
Inorg. Chem. 2011, 50, 10519–10521. 
44. Duarte, H.A.; Carvalho, S.; Paniago, E.B.; Simas, A.M. Importance of tautomers in the chemical 
behavior of tetracyclines. J. Pharm. Sci. 1999, 88, 111–120. 
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
